Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. (Q37158273)
Jump to navigation
Jump to search
scientific article published on 02 March 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. |
scientific article published on 02 March 2009 |
Statements
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma (English)
Jane N Winter
David J Inwards
Stewart Spies
Gregory Wiseman
David Patton
William Erwin
Alfred W Rademaker
Bing Bing Weitner
Stephanie F Williams
Ivana Micallef
Jayesh Mehta
Seema Singhal
Michael Zimmer
Arturo Molina
Christine A White
Martin S Tallman
1 reference
1 reference
1 reference